Veridia · Pharmaceutical quality intelligence

PHARMACEUTICAL QUALITY INTELLIGENCE

Quality intelligence.
Grounded in evidence.

An AI-assisted deviation-to-CAPA copilot in development for pharmaceutical quality teams. Connected evidence, considered drafts, and qualified human review.

SaaS initiative in development · Proposed capabilities

Veridia Quality intelligenceCONCEPTUAL INTERFACE

DEVIATION-TO-CAPA WORKSPACE

Evidence into perspective.

RetrieveInvestigateReview

Connected evidence

Process controlsSOP · Source reference
Prior investigationHistorical deviation
Supplier recordsDocument collection

Evidence-linked draft

AI-ASSISTED · FOR REVIEW

Source-grounded investigation narrative and candidate root causes.

Supporting source references
Proposed CAPAQualified reviewer approval

Illustrative workflow · Software in development

Veridia at a glance

A BlueThera software product.
Built around pharmaceutical quality.

Product
AI-assisted pharmaceutical quality software as a service (SaaS), in development
Developed by
BlueThera Biologics Inc.
Initial customers
CDMOs; pharmaceutical manufacturers as a secondary market
Development status
In development. Capabilities, technical evaluations and validation stages described here are proposed.

Veridia is being developed as a software-as-a-service (SaaS) product. It brings pharmaceutical domain expertise to a focused workflow: retrieve relevant evidence, assist investigation and CAPA drafting, and support qualified human review. Its intended role is to complement a manufacturer’s existing quality management system.

A focused quality workflow

From a deviation
to a defensible draft.

Pharmaceutical quality investigations begin with a question. The evidence is rarely in one place.

Veridia is an AI-assisted deviation-to-CAPA copilot being developed for pharmaceutical manufacturing. It is intended to bring a customer’s quality and supplier documents together with curated public regulatory information.

The proposed workflow connects investigation drafting, corrective and preventive action (CAPA) planning, and supplier context. Each is grounded in retrieved evidence and reviewed by qualified people.

The aim: less time searching and assembling documentation, with quality professionals in control of the conclusions.

Intended MVP scope

One workflow.
Connected capabilities.

Find the evidence

Document ingestion and natural-language search with citations across relevant customer records.

Investigate with context

Deviation intake, similar historical investigations and evidence-linked candidate root causes.

Draft the follow-through

Proposed investigation and CAPA documentation for quality-team review and approval.

See supplier signals

Relevant external regulatory history alongside internal evidence when supplier materials are involved.

Keep the reviewer in charge

Human editing and approval, supported by source references and a provenance log.

Work alongside the QMS

A proposed QMS-agnostic copilot intended to complement existing quality management systems.

These are intended capabilities. Product performance, workflow fit and adoption remain to be validated with customers.

Initial customer focus

Built around the
CDMO quality team.

Contract Development and Manufacturing Organizations (CDMOs) manage multiple sponsor programs, extensive quality documentation and recurring deviation-to-CAPA workflows.

They are Veridia’s initial target market. Small-to-mid pharmaceutical manufacturers are the secondary target.

Explore industry relevance

Evidence before automation

Support the decision.
Keep people accountable.

Veridia is being designed as decision support. Investigation conclusions, CAPA approval, product release and regulatory compliance remain the responsibility of the customer’s quality unit.

Product questions

A clear scope.
A responsible development plan.

How will Veridia be delivered?

Veridia’s intended business and delivery model is software as a service (SaaS). Commercial terms, deployment configuration and timing will be determined through development and customer validation.

Who is Veridia for?

CDMO quality teams are the initial target. Small-to-mid pharmaceutical manufacturers are the secondary target. Veridia is intended to complement existing quality systems.

What work is AI intended to assist?

Document retrieval, evidence-linked investigation and CAPA drafting, relevant supplier regulatory context, and a record of source references and human edits.

Can a manufacturer use Veridia today?

This website describes a software product in development and its proposed evaluation pathway. Contact BlueThera to discuss development status and potential design-partner evaluation.

Who makes the quality decisions?

Qualified quality-unit personnel retain responsibility for investigation conclusions, CAPA approval, product release and regulatory compliance.

How is customer information intended to be handled?

Customer document collections are intended to be isolated by default. Cross-customer training requires explicit customer permission and contractual safeguards. Implementation and deployment requirements will be evaluated with customers.

Discuss Veridia with BlueThera

VERIDIA BY BLUETHERA

Let’s build
with evidence.

We’re exploring technology collaborations and design-partner conversations to help shape a practical quality operations tool.

Discuss Veridia